Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

Exclusion Criteria

• •A history of hypersensitivity to opioid or psychotropic drugs.
• •A history of recurrent seizures or syncope.
• •Any medical or surgical conditions which might interfere with transdermal absorption, distribution, metabolism, or excretion of drugs.
• •Any other significant active medical illness such as: history or presence of liver disease or liver injury that is indicated by an abnormal liver function profile such as aspartate transaminase (AST), alanine transaminase (ALT), or serum bilirubin; history or presence of impaired renal function that is indicated by abnormal creatinine or blood urea nitrogen (BUN) values or abnormal urinary constituents (eg, albuminuria); history of neutropenia (absolute neutrophil count \[ANC\] \<1000/mm3 or thrombocytopenia (platelet \<150,000/mm3).
• •Positive results of urine drug screen or urine cotinine (consistent with active smoking).
• •A history of substance or alcohol abuse within the past 5 years.
• •Females who are nursing.
• •Females who are pregnant as confirmed by a positive serum human chorionic gonadotropin (bHCG) test.